Vanda Pharmaceuticals (VNDA) announced that the U.S. FDA informed Vanda that the New Drug Application for Bysanti has been filed, and that at this time no potential review issues have been identified. The FDA has set February 21, 2026 as the target date for decision on this application.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNDA:
- Vanda Pharmaceuticals (VNDA) Q1 Earnings Cheat Sheet
- Vanda says FDA ‘unlawfully’ delaying hearing
- Vanda Pharmaceuticals: Strategic Advancements and Financial Strength Underpin Buy Rating
- Vanda Pharmaceuticals submits NDA to FDA for Bysanti
- Positive Outlook for Vanda Pharmaceuticals: FDA Acceptance and Strong Financial Position Bolster Buy Rating